The Science of Red Light Therapy

Photobiomodulation (PBM) is the use of red and near-infrared light to stimulate cellular function. Unlike ultraviolet (UV) therapy, which causes chemical changes in DNA and carries risks of skin damage, PBM uses wavelengths between 600 and 1100 nanometers that do not burn, cut, or heat tissue. Unlike laser surgery, which uses focused, high-powered beams to destroy or reshape tissue, PBM applies diffuse, low-powered light to support natural biological processes.

The term “photobiomodulation” replaced the older name “low-level laser therapy” (LLLT) in 2015 when the field recognized that LEDs work just as well as lasers for most applications, and that the mechanism is not about the laser itself but about the light's interaction with biological tissue. PBM is non-thermal, meaning the therapeutic effects come from light absorption by specific molecules in your cells, not from heat. You should not feel warmth during a properly dosed session, though some high-powered panels do produce incidental heat.

At its core, PBM is simple: specific wavelengths of light are absorbed by specific molecules in your mitochondria, triggering a cascade of beneficial effects including increased energy production, reduced inflammation, and accelerated tissue repair. The challenge lies in getting the dose right, which is why understanding the underlying mechanisms matters.

The primary target of red and near-infrared light is an enzyme called cytochrome c oxidase (also known as Complex IV). This enzyme sits inside your mitochondria (the energy-producing structures within every cell) and plays a critical role in the electron transport chain (the final stage of cellular energy production).

Here is what happens when red or NIR photons reach cytochrome c oxidase. Under normal conditions, a molecule called nitric oxide (NO) binds to the enzyme and slows it down, acting like a brake on energy production. When photons at the right wavelength are absorbed, they knock the nitric oxide loose, releasing the brake. This allows electrons to flow freely through the transport chain again, which has three immediate consequences.

First, ATP production increases. ATP (adenosine triphosphate) is the universal energy currency of your cells. More ATP means cells have more fuel to perform their functions, whether that is building collagen, fighting inflammation, or repairing damaged tissue. Second, the released nitric oxide enters the surrounding tissue and acts as a vasodilator (it widens blood vessels), improving local blood flow and oxygen delivery. Third, the process generates a brief, low-level burst of reactive oxygen species (ROS). While large amounts of ROS are harmful, this small burst acts as a signaling mechanism, activating protective genes and triggering beneficial pathways including NF-kB (a key regulator of inflammation and immune response) and AP-1 (which controls cell growth and repair).

Think of it this way: the light does not heal you directly. Instead, it removes a bottleneck in your cells' energy production, giving them the resources they need to heal themselves more effectively.

One of the most important concepts in photobiomodulation is the biphasic dose response, sometimes called the Arndt-Schulz curve. This principle states that there is an optimal window of light exposure: too little light produces no meaningful effect, the right amount produces the maximum benefit, and too much light actually diminishes or reverses the therapeutic effects. More is not better.

This has been demonstrated repeatedly in both cell culture and clinical studies. In a landmark 2009 review, Huang and colleagues showed that cells exposed to low doses of light increased their proliferation and metabolic activity, while cells exposed to high doses showed inhibited growth and even cell death. The effective dose range varies by tissue type, depth, and condition, but the pattern is consistent: there is a sweet spot, and exceeding it wastes your time at best and may be counterproductive at worst.

This is why guessing your dose is problematic. A session that delivers 4 J/cm² might be therapeutic, while 40 J/cm² to the same tissue could suppress the very processes you are trying to stimulate. The biphasic response also explains why study results sometimes conflict: researchers using different doses on the same condition can get opposite results, not because the therapy does not work, but because one team hit the sweet spot and the other overshot it. Understanding your dose is essential to getting results.

Not all light is therapeutic. Human tissue has an optical window between roughly 600 and 1100 nanometers where light can penetrate meaningfully below the skin surface. Below 600nm, light is mostly absorbed by melanin and hemoglobin before it reaches target cells. Above 1100nm, water absorption dominates and the light converts to heat rather than driving photochemical reactions. Within this window, specific wavelengths are preferred because they align with the absorption peaks of chromophores (light-absorbing molecules) in your tissue, particularly cytochrome c oxidase.

The two most studied and widely used wavelengths are 660nm (visible red) and 850nm (near-infrared). Red light at 660nm has the strongest absorption by cytochrome c oxidase and penetrates roughly 8-10mm into the skin, making it ideal for surface-level applications like skin rejuvenation, wound healing, and hair growth. Near-infrared at 850nm penetrates much deeper, reaching 40-50mm into tissue, which is necessary for treating joints, deep muscles, nerves, and even brain tissue through the skull.

Other clinically relevant wavelengths include 630nm (slightly shallower, used in many FDA-cleared hair growth devices), 810nm (used extensively in transcranial PBM research for depression and cognitive health), and 830nm (an efficient deep-tissue delivery wavelength used in nerve regeneration and bone healing studies). Most quality therapy panels combine red and NIR wavelengths to cover both surface and deep tissue targets.

We believe transparency about evidence quality is essential. Not all health claims carry the same weight, and you deserve to know the difference between a well-replicated finding and a preliminary observation. Every condition page on this site includes an evidence grade based on the following system, which reflects both the quantity and quality of available research.

Photobiomodulation is not fringe science. The field has produced over 5,000 published studies and more than 300 randomized controlled trials spanning conditions from wound healing to neurodegeneration. PBM is used in clinical settings across Europe, Asia, and South America, and several devices have received FDA clearance in the United States, primarily for hair loss (510(k)) and pain management. The World Association for Laser Therapy (WALT) publishes dosing guidelines that are referenced by clinicians worldwide.

That said, an honest assessment requires acknowledging the limitations of the current evidence base. Many studies are small, with sample sizes under 50 participants. Protocols are heterogeneous: different studies use different wavelengths, doses, treatment durations, and outcome measures, making direct comparisons difficult. Publication bias is a concern, as positive results are more likely to be published than null findings. And some commercially funded studies may carry conflicts of interest.

The strongest evidence exists for wound healing, skin rejuvenation and collagen production, hair regrowth (androgenetic alopecia), and inflammation reduction. Moderate evidence supports applications in joint pain, muscle recovery, depression, and neuropathy. Preliminary evidence exists for sleep, thyroid conditions, and several other applications. We present all of this data transparently on each condition page, with grades, study references, and honest assessments of where the science stands today. Red light therapy is a promising tool with real mechanisms and real evidence, but it is not a miracle cure, and anyone who tells you otherwise is not reading the research carefully.